We are live on ! Find out more
FOMX

Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX

Delisted

FOMX was delisted on the 6th of March, 2020.

58 hedge funds and large institutions have $68.5M invested in Foamix Pharmaceuticals Ltd. Ordinary Shares in 2019 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 17 increasing their positions, 20 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

6% less funds holding

Funds holding: 6258 (-4)

15% less repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 20

40% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 10

40% less capital invested

Capital invested by funds: $115M → $68.5M (-$46.6M)

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
58
Holders Change
-4
Holders Change %
-6.45%
% of All Funds
1.26%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
6
Increased
17
Reduced
20
Closed
10
Calls
$41K
Puts
Net Calls
+$41K
Net Calls Change
-$434K
Name Holding Trade Value Shares
Change
Change in
Stake
O
1
OrbiMed
New York
$12.4M
PA
2
Perceptive Advisors
New York
$11.1M
Franklin Resources
3
Franklin Resources
California
$5.89M -$452K -151,419 -6%
DA
4
DSC Advisors
Illinois
$5.55M +$1.17M +392,676 +20%
GPP
5
Great Point Partners
Connecticut
$5.02M -$1.75M -587,062 -22%
Axa
6
Axa
France
$3.2M -$19.9K -6,676 -0.5%
SCM
7
Sio Capital Management
New York
$3.08M
SI
8
Sofinnova Investments
California
$2.65M +$847K +283,517 +34%
Millennium Management
9
Millennium Management
New York
$1.98M +$408K +136,536 +20%
DCM
10
DAFNA Capital Management
California
$1.92M
SM
11
Senvest Management
New York
$1.8M
SCM
12
Stonepine Capital Management
Oregon
$1.55M -$235K -78,793 -11%
BlackRock
13
BlackRock
New York
$1.3M -$123K -41,165 -7%
DAM
14
DLD Asset Management
New York
$1.25M +$672K +225,000 +75%
BBA
15
Baker Bros. Advisors
New York
$1.19M
First Manhattan
16
First Manhattan
New York
$1.03M -$120K -40,100 -8%
DMK
17
David M. Knott
$883K +$73.8K +24,700 +7%
Renaissance Technologies
18
Renaissance Technologies
New York
$770K +$915K +306,200 +1,760%
TCM
19
Tekla Capital Management
Massachusetts
$716K
Bank of New York Mellon
20
Bank of New York Mellon
New York
$659K -$369K -123,438 -31%
EP
21
Eversept Partners
New York
$627K -$93.4K -31,270 -11%
Baillie Gifford & Co
22
Baillie Gifford & Co
United Kingdom
$523K
Deutsche Bank
23
Deutsche Bank
Germany
$450K +$526K +175,930 +1,295%
AIM
24
ARK Investment Management
Florida
$349K +$87.8K +29,378 +25%
Wells Fargo
25
Wells Fargo
California
$310K -$46.6K -15,600 -11%

FOMX Hedge Fund Activity: Q2 2019 in Review

58 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) for Q2 2019, worth a combined $68.5M — down 40% from $115M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of FOMX and 6 opened new positions — a net loss of 4 holders — while 20 trimmed existing stakes and 17 added.

The largest buyer was DSC Advisors, adding an estimated $1.17M. The largest seller was Handelsbanken Fonder, exiting entirely with an estimated $2.55M sold.

  • 58 institutional investors held Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) as of Q2 2019, down from 62 in Q1 2019.
  • Funds reported $68.5M of Foamix Pharmaceuticals Ltd. Ordinary Shares stock for Q2 2019, down 40% quarter-over-quarter.
  • 6 funds opened new Foamix Pharmaceuticals Ltd. Ordinary Shares positions in Q2 2019 and 10 closed out, a net change of -4 holders.
  • The largest Foamix Pharmaceuticals Ltd. Ordinary Shares buyer in Q2 2019 was DSC Advisors, an estimated $1.17M added.
  • The largest Foamix Pharmaceuticals Ltd. Ordinary Shares seller in Q2 2019 was Handelsbanken Fonder, an estimated $2.55M sold.

Based on aggregated 13F filings for Q2 2019.